mTORC1型
胆固醇
内分泌学
化学
NPC1
细胞生物学
生物
生物化学
生物合成
基因
信号转导
PI3K/AKT/mTOR通路
细胞内
内体
作者
Xiao-Yi Lu,Xiongjie Shi,Ao Hu,Ju-Qiong Wang,Yi Ding,Wei Jiang,Ming Sun,Xiaolu Zhao,Jie Luo,Wei Qi,Bao‐Liang Song
出处
期刊:Nature
[Springer Nature]
日期:2020-11-11
卷期号:588 (7838): 479-484
被引量:156
标识
DOI:10.1038/s41586-020-2928-y
摘要
Cholesterol is an essential lipid and its synthesis is nutritionally and energetically costly1,2. In mammals, cholesterol biosynthesis increases after feeding and is inhibited under fasting conditions3. However, the regulatory mechanisms of cholesterol biosynthesis at the fasting-feeding transition remain poorly understood. Here we show that the deubiquitylase ubiquitin-specific peptidase 20 (USP20) stabilizes HMG-CoA reductase (HMGCR), the rate-limiting enzyme in the cholesterol biosynthetic pathway, in the feeding state. The post-prandial increase in insulin and glucose concentration stimulates mTORC1 to phosphorylate USP20 at S132 and S134; USP20 is recruited to the HMGCR complex and antagonizes its degradation. The feeding-induced stabilization of HMGCR is abolished in mice with liver-specific Usp20 deletion and in USP20(S132A/S134A) knock-in mice. Genetic deletion or pharmacological inhibition of USP20 markedly decreases diet-induced body weight gain, reduces lipid levels in the serum and liver, improves insulin sensitivity and increases energy expenditure. These metabolic changes are reversed by expression of the constitutively stable HMGCR(K248R). This study reveals an unexpected regulatory axis from mTORC1 to HMGCR via USP20 phosphorylation and suggests that inhibitors of USP20 could be used to lower cholesterol levels to treat metabolic diseases including hyperlipidaemia, liver steatosis, obesity and diabetes.
科研通智能强力驱动
Strongly Powered by AbleSci AI